Development Overview Sample Clauses

Development Overview. The term “

Development Overview. The Parties desire and intend to transition the Development of Compounds and Products from Principia to Sanofi (the “Transition”), provided that, before the completion of the Transition, Principia will conduct certain early Development activities set forth in Section 3.2 in coordination with Sanofi.

Development Overview. Nightstar intends to progress the programmes through the necessary pre-clinical, IND/CTA enabling and clinical development phases necessary to achieve regulatory product licensure in the US and EU. The programs are in various stages of pre-clinical development and will require a significant amount of activity to get clinic ready. It is anticipated that a number of IND-enabling activities are ‘pipeline’ activities; synergistic activities applicable to all the programmes, supporting the development through to entry into clinical testing.

Development Overview. The Parties shall collaborate in the development of Licensed Products up until the completion of Phase I Clinical Trials in the Field globally in accordance with the Global Development Plan and Section 4.3 below. Thereafter, the Parties may continue the development collaboration or conduct development activities in their respective territories separately in accordance with Section 4.4 below.

Development Overview. The DA seeks development consent to the subdivision and construction of three (3) residential flat buildings and ancillary works on Lot 1 DP 1226122 (development site).

Development Overview. The following provisions relate to the overall responsibility of the parties and the PMC for the development of the Products: 2.1.1 Tris shall be responsible for delivery of all Product Schedules and Product Details for the Products to the PMC. Tris shall deliver the Development Schedule for each Product by April 1, 2005. The development of each Product and the Product Plan, shall be reviewed by the PMC. During the development and regulatory review of a Product, the PMC shall meet at the call of either Party, and as required under this Agreement, at a mutually acceptable location, or by telephone. Each Party shall bear its own costs with respect to participation in the PMC. Once the Product Details are received by the PMC, the PMC shall review and discuss: (i) all development decisions regarding the Product, including, but not limited to, clinical trials and Regulatory Approvals, Patent Challenges and (ii) deciding whether to defend, and the defense of, Infringement Claims. 2.1.2 In the case of any potential patent litigation (including any litigation arising in connection with a Patent Challenge), Interpharm shall keep the PMC apprised of (i) whether it will defend an Infringement Claim and the defense of such claim, and whether it will prosecute, and prosecution of, a Tris Infringement Claim and (ii) whether it will proceed with, and/or proceeding with, a Patent Challenges. 2.1.3 In the case of a Tris Infringement Claim, if Interpharm elects not to prosecute such a Claim, Tris shall have the right to prosecute the Claim on its own. In that event, (i) Tris shall keep Interpharm reasonably apprised of the progress and status thereof on an ongoing basis; and (ii) Tris shall have the right to recover the Tris Litigation Costs associated with such litigation in accordance with Section 3.1.1, below; provided, however, that (i) such litigation relates to one or more Products, and (ii) the infringement underlying the Tris Infringement Claim would adversely affect Interpharm's Commercialization of a Product.

Development Overview. The term “Development Overview” shall have the meaning ascribed to it in Section 6.02 of this Agreement.

Development Overview. (a) Promptly following the Effective Date, Aradigm shall use Commercially Reasonable Efforts to perform the POC Study at its sole cost and expense in close consultation with Lung Rx, with the complete final report describing the results of the POC Study to be delivered to Lung Rx within a commercially reasonable period of time. (b) Following Lung Rx’s satisfaction of its payment and investment obligations set forth in Section 6.2, Lung Rx shall be primarily responsible for the Development of the Product in the Field in the Territory and shall bear all costs associated with Development of the Product in the Field in the Territory, as set forth in more detail in Section 4.6 below. (c) With respect to those Development activities assigned to a Party, such Party shall perform such Development activities using its Commercially Reasonable Efforts in accordance with the Development Plan. In addition, the Parties shall closely cooperate on all matters involved in and arising from the Development and Commercialization process of Products and the AERx pulmonary drug delivery system (and its future improvements, successors and alternatives) that may materially affect the other Party’s efforts to obtain Regulatory Approvals.

Development Overview. The Parties shall collaborate in the Development of Licensed Products under this Agreement in order to achieve a Successful Dual IND Filing for each of the [***], [***], and Reload Compound (if any), and thereafter, up until the completion of the Phase I Clinical Trial in the Field set forth in and in accordance with the Development Plan and Section 4.3 below. In the course of performance of its obligations under this Agreement, each Party shall co-operate and provide assistance to the other Party to achieve the common intent of successful Commercialization of the Licensed Products for sale in the respective territories of the Parties. Thereafter, the Parties may continue the Research Program or conduct Development activities in their respective territories separately in accordance with Section 4.4 below.